Skip to content

Xilio Therapeutics, Inc.

XLO

CIK 0001840233

← back to feed
Revenue (TTM)
$42.73M
+589.9% YoY Q1 Mar 2026
Net Income (TTM)
−$54.93M
+39.8% YoY Q1 Mar 2026
EPS Diluted (TTM)
−$3.34
+72.5% YoY Q1 Mar 2026
Gross Margin
—
Q1 Mar 2026
Operating Margin
-103.6%
Q1 Mar 2026
Net Margin
-128.5%
Q1 Mar 2026
Free Cash Flow (TTM)
−$30.12M
Q1 Mar 2026
Cash
$150.33M
Q1 Mar 2026
Total Debt
—
Q1 Mar 2026
Shares Outstanding
5.78M sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings